Proteq West Nile
West Nile fever vaccine (live recombinant)
Table of contents
Overview
Proteq West Nile is a veterinary vaccine that contains West Nile recombinant canarypox virus (vCP2017). It is available as a suspension for injection.
Proteq West Nile is used to protect horses from 5 months of age against West Nile disease. West Nile disease is a mosquito-borne viral disease that can cause encephalitis (inflammation of the brain) and meningitis (inflammation of the lining of the brain and spinal cord).The vaccine is used to reduce the number of horses with the West Nile virus in their blood (viraemia) or with clinical signs of the disease.
Authorisation details
Product details | |
---|---|
Name |
Proteq West Nile
|
Agency product number |
EMEA/V/C/002005
|
Active substance |
West Nile recombinant canarypox virus (vCP2017 virus)
|
International non-proprietary name (INN) or common name |
West Nile fever vaccine (live recombinant)
|
Species |
Horses
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI05AX
|
Publication details | |
---|---|
Marketing-authorisation holder |
Boehringer Ingelheim Vetmedica GmbH
|
Revision |
15
|
Date of issue of marketing authorisation valid throughout the European Union |
05/08/2011
|
Contact address |
55216 Ingelheim am Rhein |
Product information
14/08/2020 Proteq West Nile - EMEA/V/C/002005 - IG/1279
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunologicals
-
Immunologicals for equidae
-
Horse
Therapeutic indication
Active immunisation of horses from five months of age against West Nile disease by reducing the number of viraemic horses. If clinical signs are present, their duration and severity are reduced.